190 related articles for article (PubMed ID: 15039343)
1. Identification and molecular characterization of a gene encoding a protective Leishmania amazonensis Trp-Asp (WD) protein.
Campbell K; Popov V; Soong L
Infect Immun; 2004 Apr; 72(4):2194-202. PubMed ID: 15039343
[TBL] [Abstract][Full Text] [Related]
2. Intranasal vaccination against cutaneous leishmaniasis with a particulated leishmanial antigen or DNA encoding LACK.
Pinto EF; Pinheiro RO; Rayol A; Larraga V; Rossi-Bergmann B
Infect Immun; 2004 Aug; 72(8):4521-7. PubMed ID: 15271911
[TBL] [Abstract][Full Text] [Related]
3. Testing of four Leishmania vaccine candidates in a mouse model of infection with Leishmania (Viannia) braziliensis, the main causative agent of cutaneous leishmaniasis in the New World.
Salay G; Dorta ML; Santos NM; Mortara RA; Brodskyn C; Oliveira CI; Barbiéri CL; Rodrigues MM
Clin Vaccine Immunol; 2007 Sep; 14(9):1173-81. PubMed ID: 17626159
[TBL] [Abstract][Full Text] [Related]
4. Immune responses induced by the Leishmania (Leishmania) donovani A2 antigen, but not by the LACK antigen, are protective against experimental Leishmania (Leishmania) amazonensis infection.
Coelho EA; Tavares CA; Carvalho FA; Chaves KF; Teixeira KN; Rodrigues RC; Charest H; Matlashewski G; Gazzinelli RT; Fernandes AP
Infect Immun; 2003 Jul; 71(7):3988-94. PubMed ID: 12819086
[TBL] [Abstract][Full Text] [Related]
5. Vaccination with a plasmid DNA cocktail encoding the nucleosomal histones of Leishmania confers protection against murine cutaneous leishmaniosis.
Iborra S; Soto M; Carrión J; Alonso C; Requena JM
Vaccine; 2004 Sep; 22(29-30):3865-76. PubMed ID: 15364433
[TBL] [Abstract][Full Text] [Related]
6. DNA immunization with the gene encoding P4 nuclease of Leishmania amazonensis protects mice against cutaneous Leishmaniasis.
Campbell K; Diao H; Ji J; Soong L
Infect Immun; 2003 Nov; 71(11):6270-8. PubMed ID: 14573646
[TBL] [Abstract][Full Text] [Related]
7. Vaccination with DNA encoding the immunodominant LACK parasite antigen confers protective immunity to mice infected with Leishmania major.
Gurunathan S; Sacks DL; Brown DR; Reiner SL; Charest H; Glaichenhaus N; Seder RA
J Exp Med; 1997 Oct; 186(7):1137-47. PubMed ID: 9314562
[TBL] [Abstract][Full Text] [Related]
8. Identification and characterization of new Leishmania promastigote surface antigens, LaPSA-38S and LiPSA-50S, as major immunodominant excreted/secreted components of L. amazonensis and L. infantum.
Bras-Gonçalves R; Petitdidier E; Pagniez J; Veyrier R; Cibrelus P; Cavaleyra M; Maquaire S; Moreaux J; Lemesre JL
Infect Genet Evol; 2014 Jun; 24():1-14. PubMed ID: 24614507
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of DNA/DNA and prime-boost vaccination using LPG3 against Leishmania major infection in susceptible BALB/c mice and its antigenic properties in human leishmaniasis.
Abdian N; Gholami E; Zahedifard F; Safaee N; Rafati S
Exp Parasitol; 2011 Mar; 127(3):627-36. PubMed ID: 21187087
[TBL] [Abstract][Full Text] [Related]
10. Immunization with a recombinant stage-regulated surface protein from Leishmania donovani induces protection against visceral leishmaniasis.
Stäger S; Smith DF; Kaye PM
J Immunol; 2000 Dec; 165(12):7064-71. PubMed ID: 11120835
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of immune responses and protection induced by A2 and nucleoside hydrolase (NH) DNA vaccines against Leishmania chagasi and Leishmania amazonensis experimental infections.
Zanin FH; Coelho EA; Tavares CA; Marques-da-Silva EA; Silva Costa MM; Rezende SA; Gazzinelli RT; Fernandes AP
Microbes Infect; 2007 Jul; 9(9):1070-7. PubMed ID: 17644455
[TBL] [Abstract][Full Text] [Related]
12. A recombinant Leishmania chagasi antigen that stimulates cellular immune responses in infected mice.
Wilson ME; Young BM; Andersen KP; Weinstock JV; Metwali A; Ali KM; Donelson JE
Infect Immun; 1995 May; 63(5):2062-9. PubMed ID: 7729921
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of vaccination with a combination of Leishmania amastigote antigens and the lipid A-analogue ONO-4007 for immunoprophylaxis and immunotherapy against Leishmania amazonensis infection in a murine model of New World cutaneous leishmaniasis.
Calvopina M; Barroso PA; Marco JD; Korenaga M; Cooper PJ; Nonaka S; Hashiguchi Y
Vaccine; 2006 Jul; 24(27-28):5645-52. PubMed ID: 16621179
[TBL] [Abstract][Full Text] [Related]
14. Molecular cloning of a novel protein antigen of Leishmania major that elicits a potent immune response in experimental murine leishmaniasis.
Webb JR; Kaufmann D; Campos-Neto A; Reed SG
J Immunol; 1996 Dec; 157(11):5034-41. PubMed ID: 8943412
[TBL] [Abstract][Full Text] [Related]
15. Towards development of novel immunization strategies against leishmaniasis using PLGA nanoparticles loaded with kinetoplastid membrane protein-11.
Santos DM; Carneiro MW; de Moura TR; Fukutani K; Clarencio J; Soto M; Espuelas S; Brodskyn C; Barral A; Barral-Netto M; de Oliveira CI
Int J Nanomedicine; 2012; 7():2115-27. PubMed ID: 22619548
[TBL] [Abstract][Full Text] [Related]
16. Induction of protective CD4+ T cell-mediated immunity by a Leishmania peptide delivered in recombinant influenza viruses.
Kedzierska K; Curtis JM; Valkenburg SA; Hatton LA; Kiu H; Doherty PC; Kedzierski L
PLoS One; 2012; 7(3):e33161. PubMed ID: 22470440
[TBL] [Abstract][Full Text] [Related]
17. Protective immune response against cutaneous leishmaniasis by prime/booster immunization regimens with vaccinia virus recombinants expressing Leishmania infantum p36/LACK and IL-12 in combination with purified p36.
Gonzalo RM; Rodríguez JR; Rodríguez D; González-Aseguinolaza G; Larraga V; Esteban M
Microbes Infect; 2001 Jul; 3(9):701-11. PubMed ID: 11489418
[TBL] [Abstract][Full Text] [Related]
18. The combination of DNA vectors expressing IL-12 + IL-18 elicits high protective immune response against cutaneous leishmaniasis after priming with DNA-p36/LACK and the cytokines, followed by a booster with a vaccinia virus recombinant expressing p36/LACK.
Tapia E; Pérez-Jiménez E; López-Fuertes L; Gonzalo R; Gherardi MM; Esteban M
Microbes Infect; 2003 Feb; 5(2):73-84. PubMed ID: 12650765
[TBL] [Abstract][Full Text] [Related]
19. Total Leishmania antigens with Poly(I:C) induce Th1 protective response.
Sanchez MV; Eliçabe RJ; Di Genaro MS; Germanó MJ; Gea S; García Bustos MF; Salomón MC; Scodeller EA; Cargnelutti DE
Parasite Immunol; 2017 Nov; 39(11):. PubMed ID: 28901553
[TBL] [Abstract][Full Text] [Related]
20. The potency and durability of DNA- and protein-based vaccines against Leishmania major evaluated using low-dose, intradermal challenge.
Méndez S; Gurunathan S; Kamhawi S; Belkaid Y; Moga MA; Skeiky YA; Campos-Neto A; Reed S; Seder RA; Sacks D
J Immunol; 2001 Apr; 166(8):5122-8. PubMed ID: 11290794
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]